19 Matching Annotations
  1. Last 7 days
  2. Jun 2021
  3. May 2021
  4. Apr 2021
  5. Mar 2021
  6. Dec 2020
  7. Oct 2020
  8. Aug 2020
  9. Jul 2020
  10. Apr 2020
    1. “Even if experts are saying it’s really not going to make a difference, a little [part of] people’s brains is thinking, well, it’s not going to hurt. Maybe it’ll cut my risk just a little bit, so it’s worth it to wear a mask,” she says.
  11. May 2019
    1. first target the patients at highest risk of relapse;

      Clinical trials will most certainly first include those patients with the highest risk of relapse. However, long term, everything will depend on the risk/ benefit trade off: if an effective, simple, well-tolerated and cost-effective treatment was available (let's imagine a single short low-dose PD1 for any early Melanoma patient) that prevented progression for most patients would be very different from a highly toxic, expensive treatment that doesn't work for everyone (think Ipi 10mg/kg adjuvant)- so everything is in the trade-off

  12. Dec 2016